Features, Advantages, Benefits and Comparisons ORLANDO, FL, UNITED STATES, April 2, 2026 /EINPresswire.com/ -- A ...
Sobers guided for Q4 2025 revenue in the range of $76 million to $78 million, representing 14% year-over-year growth at the midpoint, with gross margin in the range of 78% to 79% and adjusted EBITDA ...
That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient (DTP) programs. In the last few months alone, Amgen, Bristol Myers Squibb, AstraZeneca, Genentech, Novartis ...
CEO James Reinhart highlighted "the third quarter was our strongest year-over-year growth in nearly 4 years and the fourth quarter in a row of accelerating growth." He reported revenue growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results